Regenerative Medicine · Health & Wellness
Stem Cell Therapy for Back Pain: Disc Injections, Trial Results and Risks

Back pain is one of the hardest problems in medicine to treat well and one of the easiest to sell to. It is common, it waxes and wanes on its own and it often has no single clear cause on a scan. Those same features make it a poor fit for judging a treatment by how people feel afterward, and a good fit for clinics offering "stem cell" injections.
Researchers have tested cell injections for back pain for close to two decades, mostly for pain thought to come from worn spinal discs. The better the trials have become, the smaller the benefit has looked. Here is what is on offer, what the controlled studies found and how to protect yourself. Treat it as background for a conversation with your doctor or a spine specialist, not a substitute for one.
Where the needle goes
Clinic marketing rarely says exactly where an injection will be placed, but the target matters for both risk and evidence.
| Target | What it means | Evidence for cell injections |
|---|---|---|
| The disc (intradiscal) | A needle into the center of a lumbar disc under X-ray guidance | Several randomized trials, summarized below |
| Facet or sacroiliac joints | Small joints at the back of the spine and the pelvis | Small studies only |
| Epidural space | Around the nerve roots, as with a steroid epidural | Little or no controlled data |
| Muscles and ligaments | Injections along the spine at painful spots | Little or no controlled data |
| Spinal fluid or a vein | Marketed for back pain alongside many other conditions | None for back pain; serious harms reported |
The products are the same ones sold for knees: bone marrow concentrate drawn from the hip, fat-derived stromal vascular fraction (SVF) from liposuction, and "amniotic" or "umbilical cord" products bought from suppliers. Some clinics also inject platelet-rich plasma (PRP), which contains no stem cells, or "exosomes," which contain no cells at all. Research programs have tested a fourth group, lab-grown donor mesenchymal stromal cells, made under drug manufacturing rules and given only in trials. Our page on bone marrow and mesenchymal stromal cells explains what those cells are and what they do.
What sham-controlled disc trials found
The disc is the one target with real trials, and their pattern is consistent. People in every group improve, including those who receive only a sham procedure, and the cell groups rarely do better.
| Trial | Journal and year | Who was treated | Main finding |
|---|---|---|---|
| Phase 3, donor mesenchymal precursor cells, 49 sites | The Spine Journal, 2025 | 404 adults with chronic low back pain and moderate disc degeneration | Main endpoint not met for either cell group compared with saline |
| RESPINE, donor bone marrow stromal cells | Annals of the Rheumatic Diseases, 2024 | 114 adults with chronic low back pain | Responders at 12 months: 74% with cells, 69% with sham, not a meaningful difference |
| DREAM, the patient's own marrow cells, phase 2b | JOR Spine, 2025 | 52 adults with disc degeneration at up to three levels | Disc height on MRI improved, but pain, disability and quality of life improved equally with sham at 6 months |
Three details are worth knowing.
The phase 3 trial was large, double-blind and run at dozens of centers, which is what regulators look for. After it missed its main goal, its report emphasized better results in a prespecified subgroup of people whose pain had lasted less than the median of 68 months. Subgroup findings in a trial that missed its primary endpoint are generally treated as ideas to test again, not as proof.
RESPINE was a multicenter European trial with a careful sham control. Most people in both groups met its definition of a responder, which shows how much chronic back pain can improve with time, attention and expectation alone.
DREAM found what many patients would call a better-looking disc on MRI without any extra pain relief. In the spine, images and symptoms often disagree, which is one reason a clinic's before-and-after scans should not persuade you.
Reviews that pool all the studies, including uncontrolled ones, reach cautious conclusions. A 2019 systematic review in Global Spine Journal rated the strength of evidence for disc cell therapy as very low. A 2022 review of bone marrow concentrate and marrow cell injections in the Journal of Pain Research found that patients generally improved from baseline, but rated the certainty of the evidence as very low and noted one case of disc infection.
What the FDA says
The FDA has approved no stem cell, SVF, cord blood, amniotic or exosome product for back pain or disc disease. Its consumer information page names disc disease, back pain and neck pain among the conditions these products have not been approved to treat.
The legal reason clinics give for selling them anyway rests on a narrow exemption for lightly processed tissue that does the job it did in the body, known as a 361 product. Anything more processed, or used for a new purpose, is a 351 product and needs an investigational new drug application (IND) and an approval, like any drug. Fat cells injected into a disc, or birth tissue injected along the spine, are not doing their natural job, and two federal appeals courts have ruled that fat-derived SVF is a drug requiring approval. Our earlier piece on the cost and legal status of stem cell therapy explains that test in more detail.
Harms specific to the spine
The spine is a closed space with nerves running through it, so infections and growths there can be devastating.
- Spinal infections. In 2018 the CDC described 12 patients hospitalized after injections of bacterially contaminated umbilical cord blood products. Some had been treated for low back pain, and their infections included epidural abscesses, discitis (infection of the disc space) and vertebral osteomyelitis (infection of the spinal bone). Bacteria grew from unopened vials.
- A growth in the spinal cord. In 2016 the New England Journal of Medicine described a man who received stem cell injections into his spinal fluid at clinics abroad after a stroke and later developed a mass in his spinal cord made of cells that were not his own.
- Disc injury. Any needle into a disc carries a small risk of infection and may speed up degeneration, which is why trials use strict sterile technique and imaging guidance.
- Harms at the harvest site. Liposuction and marrow draws carry their own bleeding, pain and infection risks.
Before you agree to a spine injection
- Ask exactly where the needle will go and whether imaging will guide it.
- Ask what product will be injected, where it comes from and how it was tested for sterility. "Proprietary" is not an answer.
- Ask whether it is FDA approved for your diagnosis and, if not, for the IND number.
- Ask for published, sham-controlled results for that product at that target.
- Ask who treats complications and whether the clinic can admit patients to a hospital.
- Ask for a written total price, including any repeat rounds.
Bring the answers to your primary care doctor or a spine specialist. Our guide to the warning signs of unproven stem cell clinics lists more red flags, and our piece on stem cell injections for knee pain sets a regulated trial and a cash-pay protocol side by side.
A note on cost
We found no published price survey specific to back pain stem cell injections that we could verify. The best-known survey looked at knees: in The Journal of Knee Surgery in 2018, a simulated patient was quoted an average of about 5,160 dollars for one same-day knee injection, with quotes from about 1,150 to 12,000 dollars. Treat that only as a rough reference. Insurers generally do not cover these injections, and repeat rounds are common.
What has evidence for chronic low back pain
The American College of Physicians' 2017 guideline, published in Annals of Internal Medicine, recommends starting care for chronic low back pain with treatments that do not involve drugs: exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, cognitive behavioral therapy and spinal manipulation, among others. Medicines come next for people who do not improve enough. A specialist can also look for specific causes, such as a compressed nerve, that have their own treatments.
If a cell therapy still interests you, the place for it is a registered trial. On ClinicalTrials.gov, search "degenerative disc disease" or "discogenic low back pain," filter to recruiting interventional studies and look for a sham or placebo group, an academic or established industry sponsor and no charge for the product. A study with all three is the only setting in which a disc injection of cells belongs right now.
This explainer is general information, not medical advice. Decisions about treatment, donation or trials belong with a clinician who knows your history.



